Clinical Trial Update: A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo [Phase 2]

View source ↗

Summary

Phase 2 study assessing the safety and efficacy of topical ruxolitinib cream for nonsegmental vitiligo with genital involvement; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vitiligo

Drugs mentioned

• OPZELURA (Ruxolitinib) Cream (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Nonsegmental Vitiligo With Genital Involvement | Phase 2 | Status: COMPLETED | Results posted: 2026-03-20